230 related articles for article (PubMed ID: 28244062)
81. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
Alniemi DT; Fischer A; Greene LA; Pierson JC
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
[TBL] [Abstract][Full Text] [Related]
82. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
Henderson P
JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939848
[No Abstract] [Full Text] [Related]
83. Celecoxib-induced Sweet's syndrome.
Fye KH; Crowley E; Berger TG; LeBoit PE; Connolly MK
J Am Acad Dermatol; 2001 Aug; 45(2):300-2. PubMed ID: 11464196
[TBL] [Abstract][Full Text] [Related]
84. First report of ipilimumab-induced Grover disease.
Munoz J; Guillot B; Girard C; Dereure O; Du-Thanh A
Br J Dermatol; 2014 Nov; 171(5):1236-7. PubMed ID: 24749658
[No Abstract] [Full Text] [Related]
85. Second primary melanomas on treatment with vemurafenib.
Dalle S; Poulalhon N; Debarbieux S; Thomas L
Br J Dermatol; 2013 Apr; 168(4):887-8. PubMed ID: 23066856
[No Abstract] [Full Text] [Related]
86. Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib.
Finelt N; Lulla RR; Melin-Aldana H; Ruth JS; Lin FY; Su JM; Pourciau CY; Hunt RD; Kenner-Bell BM
Pediatr Dermatol; 2017 May; 34(3):337-341. PubMed ID: 28523881
[TBL] [Abstract][Full Text] [Related]
87. Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Furudate S; Fujimura T; Kambayashi Y; Hidaka T; Sato Y; Tanita K; Hashimoto A; Aiba S
J Dermatol; 2017 Sep; 44(9):e226-e227. PubMed ID: 28439948
[No Abstract] [Full Text] [Related]
88. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
89. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
[TBL] [Abstract][Full Text] [Related]
90. Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event.
Herms F; Franck N; Kramkimel N; Fichel F; Delaval L; Laurent-Roussel S; Carlotti A; Avril MF
Br J Dermatol; 2017 Jun; 176(6):1645-1648. PubMed ID: 28005274
[TBL] [Abstract][Full Text] [Related]
91. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
92. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
93. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
Huang V; Hepper D; Anadkat M; Cornelius L
Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
[TBL] [Abstract][Full Text] [Related]
94. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
[TBL] [Abstract][Full Text] [Related]
95. Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma.
Kato J; Hida T; Kamiya T; Sato S; Takahashi H; Torigoe T; Uhara H
JAMA Dermatol; 2018 May; 154(5):621-622. PubMed ID: 29590278
[No Abstract] [Full Text] [Related]
96. Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease.
Coleman E; Panse G; Cowper S; Prebet T; Gore S; Leventhal J
J Cutan Pathol; 2019 Dec; 46(12):930-934. PubMed ID: 31254406
[TBL] [Abstract][Full Text] [Related]
97. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
98. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
99. Generalized pustular psoriasis-like drug eruption manifested by systemic glucocorticosteroid in a patient without IL36RN mutation or an immunological disorder.
Sakai T; Matsuda-Hirose H; Shimada H; Sugiura K; Hatano Y
Eur J Dermatol; 2020 Apr; 30(2):183-184. PubMed ID: 32538361
[No Abstract] [Full Text] [Related]
100. INTRAVITREAL METHOTREXATE IN VEMURAFENIB-INDUCED UVEITIS.
Dugauquier A; Awada AH; Motulsky E; Kisma N
Retin Cases Brief Rep; 2024 Jul; 18(4):455-458. PubMed ID: 36977328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
